ClinicalTrials.gg
CompletedNCT05315947Updated Jan 5, 2024Results posted

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

A Phase 1 interventional study of brivaracetam and brivaracetam in Healthy Study Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in Japan. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Study summary

The purpose of the study is to demonstrate the bioequivalence between the BRV tablet and BRV as dry syrup after a single oral dose in healthy Japanese male study participants.

02

Conditions studied

  • Healthy Study Participants

Keywords

  • brivaracetam
  • Healthy Study Participants
  • Phase 1
  • BRV
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be between 20 to 50 years of age (inclusive) at the time of signing the Form (ICF)
  • Study participant is overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Study participant is of Japanese descent as evidenced by appearance and verbal confirmation of familial heritage (a study participant has all 4 Japanese grandparents born in Japan)

Exclusion criteria

Exclusion criteria:

  • Study participant has used other drugs, including over-the-counter medications, herbal/traditional medicines, or dietary supplements (excluding medicines for external use),with the exception of paracetamol, within 14 days before first administration of IMP or has received a coronavirus disease 2019 (COVID-19) vaccine within 7 days of initiating IMP
  • Study participant has used hepatic enzyme-inducing drugs (eg, , phenobarbital, isoniazid, phenytoin, rifampicin) within 2 months before the first administration of Medicinal Product (IMP)
  • Study participant has a positive result for surface antigen, virus antibody test, antibody test, or syphilis at Screening Visit
  • Study participant has donated blood or plasma or has experienced blood loss ≥400 mL within 90 days, ≥200 mL within 30 days, or has donated any blood or plasma within 14 days before first administration of IMP
  • Study participant is a current smoker or has used nicotine-containing products (eg, tobacco, patches, gum) within 30 days before the first administration of IMP
  • Consumption of more than 600 mg of caffeine/day (1 cup of coffee contains approximately 100mg of caffeine, 1 cup of tea approximately 30 mg, and 1 glass of cola approximately 20 mg)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A-B

    Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence A-B at pre-specified timepoints.

    Drug: brivaracetam

  • Experimental
    Treatment B-A

    Study participants randomized to this arm will receive a single dose of brivaracetam tablet (Treatment A) as reference and single dose of brivaracetam dry syrup (Treatment B) as test in the treatment sequence B-A at pre-specified timepoints.

    Drug: brivaracetam

Interventions

  • Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.

    Also known as: BRV, Briviact

  • Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.

    Also known as: BRV, Briviact

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) for a Single Dose of Brivaracetam

    Cmax is the maximum plasma concentration of brivaracetam.

    Time frame: Blood samples for this analysis were collected on Predose (Day 1), 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

  2. Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration (AUC(0-t)) for a Single Dose of Brivaracetam

    AUC(0-t) is the area under the curve from time 0 to the time of the last quantifiable concentration.

    Time frame: Blood samples for this analysis were collected on Predose (Day 1), 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

Secondary outcomes

  1. Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

    An AE was defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. A TEAE was defined as any AE with a start date/time on or after the first dose of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to IMP.

    Time frame: From Baseline to end of Safety Follow-Up, up to 20 days

  2. Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE)

    A TEAE was any AE with a start date/time on or after the first dose of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to IMP. A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: Results in death, Is life-threatening, Requires in patient hospitalization or prolongation of existing hospitalization,Is a congenital anomaly or birth defect, Is an infection that requires treatment parenteral antibiotics, Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Baseline to end of Safety Follow-Up, up to 20 days

07

Results

Posted Jan 5, 2024

Participant flow

The study started to enroll participants in April 2022 and concluded in May 2022.

Participant flow — Overall Study
MilestoneTreatment A-B (Sequence: BRV Tablet - BRV Dry Syrup)Treatment B-A (Sequence: BRV Dry Syrup - BRV Tablet)
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) for a Single Dose of Brivaracetam

Cmax is the maximum plasma concentration of brivaracetam.

Time frame:
Blood samples for this analysis were collected on Predose (Day 1), 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Maximum Plasma Concentration (Cmax) for a Single Dose of Brivaracetam
micrograms per milliliter (μg/mL)BRV TabletBRV Dry Syrup
Maximum Plasma Concentration (Cmax) for a Single Dose of Brivaracetam2.286 ± 24.51.989 ± 22.4
Statistical analysis
  • BRV Tablet vs BRV Dry Syrup · Ratio of dry syrup/ tablet: 0.8700 · 90% CI 0.7814 to 0.9686
PrimaryArea Under the Curve From 0 to the Time of the Last Quantifiable Concentration (AUC(0-t)) for a Single Dose of Brivaracetam

AUC(0-t) is the area under the curve from time 0 to the time of the last quantifiable concentration.

Time frame:
Blood samples for this analysis were collected on Predose (Day 1), 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose
Reported as:
Geometric mean · hours*μg/mL
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration (AUC(0-t)) for a Single Dose of Brivaracetam
hours*μg/mLBRV TabletBRV Dry Syrup
Area Under the Curve From 0 to the Time of the Last Quantifiable Concentration (AUC(0-t)) for a Single Dose of Brivaracetam17.98 ± 17.017.78 ± 16.2
Statistical analysis
  • BRV Tablet vs BRV Dry Syrup · Ratio of dry syrup/ tablet: 0.9890 · 90% CI 0.9756 to 1.003
SecondaryPercentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

An AE was defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. A TEAE was defined as any AE with a start date/time on or after the first dose of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to IMP.

Time frame:
From Baseline to end of Safety Follow-Up, up to 20 days
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
percentage of participantsBRV TabletBRV Dry Syrup
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)37.537.5
SecondaryPercentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE)

A TEAE was any AE with a start date/time on or after the first dose of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to IMP. A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: Results in death, Is life-threatening, Requires in patient hospitalization or prolongation of existing hospitalization,Is a congenital anomaly or birth defect, Is an infection that requires treatment parenteral antibiotics, Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.

Time frame:
From Baseline to end of Safety Follow-Up, up to 20 days
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE)
percentage of participantsBRV TabletBRV Dry Syrup
Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE)00

Adverse events

Collected over From Baseline to end of Safety Follow-Up, up to 20 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BRV Tablet0/24 (0%)0/24 (0%)9/24 (37.5%)
BRV Dry Syrup0/24 (0%)0/24 (0%)8/24 (33.3%)
Most frequent other events
Most frequent other events
EventBRV TabletBRV Dry Syrup
SomnolenceNervous system disorders7/246/24
DizzinessNervous system disorders5/243/24

Baseline characteristics

Baseline Characteristics refer to the Safety Set (SS) which consisted of all randomized study participants who received at least 1 dose of the investigational medicinal product (IMP).

Age, Categorical
Age, Categorical(Participants)BRV (All Participants)
<=18 years0
Between 18 and 65 years24
>=65 years0
Age, Continuous
Age, Continuous(years)BRV (All Participants)
Mean34.5 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)BRV (All Participants)
Female0
Male24
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BRV (All Participants)
Asian24
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BRV (All Participants)
Not Hispanic or Latino24
08

Study locations

1 site
  • EP0110 1
    Sumida-ku, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2022, 1 month.

Results were first posted in Jan 2024, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2022
First posted
Apr 7, 2022
StartActual
Apr 4, 2022
Primary completionActual
May 13, 2022
CompletionActual
May 13, 2022
Results first posted
Jan 5, 2024
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05315947
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
Apr 4, 2022
Primary completion
May 13, 2022
Completion
May 13, 2022
Results posted
Jan 5, 2024
Last update
Jan 5, 2024

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion